Procter & Gamble Hygiene Revenue Up 2.3% to ₹1,160 Cr
06 Nov 2025
Abbott India Q2 FY26 financial results analysis with strong revenue growth and profitability improvement
₹ 29,478
+0.38% increased today
06 Nov - close price
Financial Performance Overview
Mumbai, India, November 6, 2025: Abbott India Limited announced its unaudited financial results for the quarter ended 30th September 2025, delivering strong revenue growth of 8.2% and impressive PAT growth of 15.8%, demonstrating robust performance in the pharmaceutical segment.
Key Financial Highlights (Q2 FY26)
Revenue
₹1,757.15 Cr
+8.2% YoY
Profit Before Tax
₹545.93 Cr
+13.9% YoY
PAT
₹415.27 Cr
+15.8% YoY
Basic EPS
₹195.41
+15.8% YoY
Quarterly Performance Comparison
| Financial Metric | Q2 FY26 | Q2 FY25 | YoY Change | Performance |
|---|---|---|---|---|
| Revenue (₹ Cr) | 1,757.15 | 1,623.67 | +8.2% | Strong |
| Profit Before Tax (₹ Cr) | 545.93 | 479.42 | +13.9% | Excellent |
| PAT (₹ Cr) | 415.27 | 358.61 | +15.8% | Outstanding |
| Basic EPS (₹) | 195.41 | 168.76 | +15.8% | Excellent |
Six Months Performance (H1 FY26)
Half Yearly Financial Summary
H1 Revenue
₹3,495.50 Cr
+9.6% YoY
H1 PAT
₹781.13 Cr
+13.8% YoY
H1 EPS
₹367.59
+13.8% YoY
Business Segment Performance
Single Business Segment - Pharmaceuticals
📊 Revenue Composition
Expense Analysis
Cost Structure (Q2 FY26)
Cost of Materials
₹163.59 Cr
Purchases of Stock-in-trade
₹733.32 Cr
Employee Benefits
₹158.88 Cr
Other Expenses
₹159.15 Cr
Balance Sheet Strength
Financial Position as of September 30, 2025
Total Assets
₹5,694.46 Cr
Total Equity
₹4,010.91 Cr
Cash & Equivalents
₹591.10 Cr
Bank Balances
₹688.15 Cr
Total Debt
₹182 Cr
Minimal
Cash Flow Performance
Cash Flow Highlights (H1 FY26)
Operating Cash Flow
₹521.94 Cr
Investing Cash Flow
₹548.35 Cr
Financing Cash Flow
-₹1,039.78 Cr
Dividend Payment
Note: Negative financing cash flow primarily due to dividend payment of ₹1,009.34 Cr, demonstrating strong shareholder returns.
Stock Performance & Key Metrics
Abbott India Stock Analysis
Market Cap
₹62,628 Cr
Current Price
₹29,478
52W High / Low
₹37,000 / 25,260
Stock P/E
41.5
Book Value
₹1,888
Dividend Yield
1.61%
ROCE
46.2%
ROE
35.7%
Face Value
₹10.0
EPS
₹710
Debt to Equity
0.05
Total Debt
₹182 Cr
About Abbott India Limited
Company Overview
Abbott India Limited is one of India's leading pharmaceutical companies with a strong portfolio of pharmaceutical products, nutritional products, and medical devices. The company is a subsidiary of Abbott Laboratories, USA, and has a significant presence in the Indian healthcare market.
🎯 Business Highlights
Overall Performance Assessment: Abbott India delivered an outstanding Q2 FY26 performance with 8.2% revenue growth and impressive 15.8% PAT growth, demonstrating strong operational efficiency and market position. The company maintains excellent profitability metrics with ROCE of 46.2% and ROE of 35.7%, supported by a robust balance sheet with minimal debt. The significant dividend payment of over ₹1,009 Cr highlights the company's commitment to shareholder returns. The stock trades at a premium P/E of 41.5, reflecting the market's confidence in Abbott India's strong brand equity, consistent performance, and growth prospects in the pharmaceutical sector.
